NRG Oncology/RTOG 0937: Randomized Phase 2 Study Comparing Prophylactic Cranial Irradiation (PCI) Alone to PCI and Consolidative Extracranial Irradiation for Extensive Disease Small Cell Lung Cancer (ED-SCLC)

Publication date: 1 January 2016
Source:International Journal of Radiation Oncology*Biology*Physics, Volume 94, Issue 1
Author(s): E.M. Gore, C. Hu, A. Sun, D. Grimm, S. Ramalingam, N.E. Dunlap, K.A. Higgins, M. Werner-Wasik, A.M. Allen, P. Iyengar, G.M. Videtic, R.K. Hales, R.C. McGarry, J.J. Urbanic, A.T. Pu, C. Johnstone, J.N. Atkins, J.D. Bradley




from Cancer via ola Kala on Inoreader http://ift.tt/1QcsiUj
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1IMsyqh
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1lXgGqW
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1QlWkor
via IFTTT

Primary Study Endpoint Analysis for NRG Oncology/RTOG 0813 Trial of Stereotactic Body Radiation Therapy (SBRT) for Centrally Located Non-Small Cell Lung Cancer (NSCLC)

Publication date: 1 January 2016
Source:International Journal of Radiation Oncology*Biology*Physics, Volume 94, Issue 1
Author(s): A. Bezjak, R. Paulus, L.E. Gaspar, R.D. Timmerman, W.L. Straube, W.F. Ryan, Y. Garces, A.T. Pu, A.K. Singh, G.M. Videtic, R.C. McGarry, P. Iyengar, J.R. Pantarotto, J.J. Urbanic, A. Sun, M.E. Daly, I.S. Grills, D.P. Normolle, J.D. Bradley, H. Choy




from Cancer via ola Kala on Inoreader http://ift.tt/1Z5LG6O
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1Ma8tFc
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1OZCxd1
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1Niu0j2
via IFTTT

In Regard to Canyilmaz et al

Publication date: 1 January 2016
Source:International Journal of Radiation Oncology*Biology*Physics, Volume 94, Issue 1
Author(s): Daniel E. Roos, Jennifer G. Smith




from Cancer via ola Kala on Inoreader http://ift.tt/1Z5LG6I
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1IMsyqd
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1lXgIPw
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1QlWmN5
via IFTTT

Treatment Responses and Survival in IDH1-Mutant Grade II and III Gliomas in NRG Oncology/RTOG 9802 and 9813

Publication date: 1 January 2016
Source:International Journal of Radiation Oncology*Biology*Physics, Volume 94, Issue 1
Author(s): E.H. Bell, P. Zhang, J.C. Buckner, S.M. Chang, A.L. Salavaggione, D. Brachman, R.J. Lee, A.D. Murtha, P.D. Brown, C.J. Schultz, S. Malone, M.P. Mehta, S.L. Pugh, A. Chakravarti




from Cancer via ola Kala on Inoreader http://ift.tt/1Z5LG6E
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1IMsuXD
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1OZCv4O
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1QlWmN3
via IFTTT

Image-guided cervical brachytherapy: 2014 survey of the American Brachytherapy Society

Publication date: Available online 11 December 2015
Source:International Journal of Radiation Oncology*Biology*Physics
Author(s): Surbhi Grover, Matthew M. Harkenrider, Linda P. Cho, Beth Erickson, Christina Small, William Small, Akila Viswanathan
IntroductionTreatment planning for gynecologic brachytherapy has evolved from point-based planning to volume-based, image-based planning with the goal of improving tumor control and lessening normal-tissue toxicity. The American Brachytherapy Society (ABS) conducted a survey in 2007, which showed although computed tomography (CT) was often used for treatment planning, most used point A for dose specification. This study is an update of the previous survey to assess treatment patterns and compare them to the 2007 results.MethodsA 45-question electronic survey on cervical-cancer brachytherapy practice patterns was sent to all ABS members and additional radiation oncologists and physicists based in the United States (U.S.) between January and September 2014. Responses from the 2007 survey and the current survey were compared using the chi-squared test.ResultsThere were 370 respondents. Of those, only respondents, not in training, who treat more than one cervical-cancer patient a year and practice in the U.S., were included in the analysis (219). For dose specification to the target, (cervix and tumor) 95% always use CT and 34% always use MRI. However, 46% use point A only for dose specification to the target. There was a lot of variation in parameters used for dose evaluation of target volume and normal tissues. Compared to the 2007 survey, use of MRI has increased from 2% to 34% (p<0.0001) for dose specification to the target. Use of volume-based dose delineation to the target has increased from 14% to 52% (p<0.0001).ConclusionAlthough use of IBBT has increased in the U.S. since the 2007 survey, there is room for further growth, particularly with the use of MRI. This increase may be in part due to educational initiatives. However, there is still significant heterogeneity in brachytherapy practice in the U.S. and future efforts should be geared toward standardizing treatment.

Teaser

The American Brachytherapy Society conducted a survey of image-guided cervical brachytherapy practices in the United States in 2007, which showed that most physicians used CT for planning and used a point-based system only for target-dose prescription. We present the updated results of a 2014 practice pattern survey showing that, compared to 2007, it appears that significantly more physicians are using CT and MRI for planning and more physicians are using a volume-based system for target-dose prescription.


from Cancer via ola Kala on Inoreader http://ift.tt/1Z5LG6y
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1Ma8tEY
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1lXgIPu
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1Niu0iY
via IFTTT

A Prognostic Analysis on Using the Combination of Tumor Volume and Epstein-Barr Virus DNA in Patients With Nasopharyngeal Carcinoma Treated With IMRT

Publication date: 1 January 2016
Source:International Journal of Radiation Oncology*Biology*Physics, Volume 94, Issue 1
Author(s): L. Lu, J. Li, W. Jia, C. Zhao, T. Lu




from Cancer via ola Kala on Inoreader http://ift.tt/1Z5LFQ6
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1IMsuXx
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1OZCxcT
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1QlWkol
via IFTTT

Urinary 1-hydroxypyrene concentration as an exposure biomarker to polycyclic aromatic hydrocarbons (PAHs) in Mexican women from different hot spot scenarios and health risk assessment

Abstract

Recently, in developing countries, polycyclic aromatic hydrocarbons (PAHs) have been considered contaminants of grave concern for women and children. Therefore, the aim of this study was twofold: (1) evaluate exposure assessment to PAHs using urinary 1-hydroxypyrene (1-OHP) as an exposure biomarker and (2) perform a health risk assessment in women from four different high risk scenarios in Mexico. From 2012 to 2013, in a cross-sectional study, we evaluated a total of 184 healthy women from the following scenarios: (A) indoor biomass combustion site (n = 50); (B) brick manufacturing site using different materials such as fuel sources (n = 70); (C) industrial site (n = 44); and (D) high vehicular traffic site (n = 20). 1-hydroxypyrene (1-OHP) was quantified using a high-performance liquid chromatography (HPLC) technique. Afterward, a probabilistic health risk assessment was performed (Monte Carlo analysis). Mean urinary 1-OHP levels found were 0.92 ± 0.92; 0.91 ± 0.83; 0.22 ± 0.19; and 0.14 ± 0.17 μg/L for scenario A, B, C, and D, respectively. Then, based on the measured urinary 1-OHP levels, the estimated median daily intake doses of pyrene were calculated: 659, 623, 162, and 77.4 ng/kg/day for the women participating in the study living in areas A, B, C, and D, respectively, and finally, the hazard quotient (HQ) was calculated (22 ± 21, 21 ± 20, 5.5 ± 5.5, and 2.6 ± 3.5; for areas A, B, C, and D, respectively), high health risk was noted for the women living in the studied communities. The data shown in this study (exposure levels to PAHs and health risk assessment) made it reasonable to conclude that the exposure levels found have a significant potential for generating adverse effects on human health in the studied scenarios.

from #Dermatology via alexandrossfakianakis on Inoreader http://ift.tt/1mgWpgx
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1Ma8tow
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1lXgIzc
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1Niu3ez
via IFTTT